Enveda Banks $311M Series E to Push AI-Designed Drugs Through Clinic
Enveda Biosciences raised $311 million in a Series E led by Catalio Capital to advance three AI-designed drugs in human testing for eczema, asthma, obesity and inflammatory bowel disease.